We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 19, 2022

Sugemalimab in Combination With Platinum-Based Chemotherapy as First-Line Treatment of Metastatic NSCLC

The Lancet Oncology


Additional Info

The Lancet Oncology
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
Lancet Oncol 2022 Jan 14;[EPub Ahead of Print], C Zhou, Z Wang, Y Sun, L Cao, Z Ma, R Wu, Y Yu, W Yao, J Chang, J Chen, W Zhuang, J Cui, X Chen, Y Lu, H Shen, J Wang, P Li, M Qin, D Lu, J Yang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading